Brief: Aridis’ AR-301 Monoclonal Antibody Receives FDA’S Qualified Infectious Diseases Product Designation
12/07/2023 14:35
July 12 (Reuters) - Aridis Pharmaceuticals Inc ARDS.O :
* ARIDIS’ AR-301 MONOCLONAL ANTIBODY IS AMONG THE FIRST
BIOLOGICS
TO RECEIVE FDA’S QUALIFIED INFECTIOUS DISEASES PRODUCT (QIDP)
DESIGNATION
Source text for Eikon: ID:nGNX3v1knZ
Further company coverage: ARDS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aridis Pharmaceuticals
See all newsBrief: Aridis Pharmaceuticals Inc - On September 7 Nasdaq Announced That It Would Delist Common Stock Of Co
U.S. STOCKS ON THE MOVE-Pieris Pharma, Microsoft, Energy sector
U.S. STOCKS ON THE MOVE-Medtronic, Morgan Stanley, Bank of America
U.S. STOCKS ON THE MOVE-Teladoc Health, NVDIA, Chipotle
U.S. STOCKS ON THE MOVE-Pinterest, Sunrun, Tencent Music